Nook Biosciences

Microbiome-focused biopharmaceutical holding company

Business Model
B2B

About

Nook Biosciences is a US-based biopharmaceutical holding company focused on the microbiome and gut biology space. The company is referenced in peer-reviewed scientific literature, with leading microbiome researchers including Dr. Andrew Goodman of Yale University serving on its scientific advisory board. Nook Biosciences appears to be engaged in the development of therapeutic approaches leveraging gut bacteria and microbiome science, operating in proximity to academic centers of excellence in the US. The company is classified as a holding company structure in biopharma databases, suggesting it may house or incubate multiple therapeutic programs or subsidiaries targeting microbial-based treatments. Given its association with top-tier academic advisors in the microbiome field and its listing on biopharma intelligence platforms such as Patsnap Synapse, Nook Biosciences is positioned in the preclinical or early clinical stage of drug development. Specific details on pipeline indications, funding rounds, or headcount remain limited in public sources.

Summary

Nook Biosciences is a Biotech company based in United States.

Similar Companies